prikaz prve stranice dokumenta Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)
  Download
PDF 705.27 KB
Scientific paper - Original scientific paper
Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)
Medicina, 60 (2024), 3; 430. https://doi.org/10.3390/medicina60030430
Hude Dragičević, Ida; Bašić-Kinda, Sandra; Markotić, Helena; Morić-Perić, Martina; Dujmović, Dino; Radman, Ivo; Dreta, Barbara; Dotlić, Snježana; Ilić, Ivana; Galunić Bilić, Lea; Dobrenić, Margareta; Kralik, Marko; Aurer, Igor

Cite this document

Hude Dragičević, I., Bašić Kinda, S., Markotić, H., Morić Perić, M., Dujmović, D., Radman, I. ... Aurer, I. (2024). Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP). Medicina, 60. (3). doi: 10.3390/medicina60030430

Hude Dragičević, Ida, et al. "Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)." Medicina, vol. 60, no. 3, 2024. https://doi.org/10.3390/medicina60030430

Hude Dragičević, Ida, Sandra Bašić Kinda, Helena Markotić, Martina Morić Perić, Dino Dujmović, Ivo Radman, Barbara Dreta, et al. "Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)." Medicina 60, no. 3 (2024). https://doi.org/10.3390/medicina60030430

Hude Dragičević, I., et al. (2024) 'Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)', Medicina, 60(3). doi: 10.3390/medicina60030430

Hude Dragičević I, Bašić Kinda S, Markotić H, Morić Perić M, Dujmović D, Radman I, and sur.. Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP). Medicina [Internet]. 2024 March 02 [cited 2024 November 07];60(3). doi: 10.3390/medicina60030430

I. Hude Dragičević, et al., "Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)", Medicina, vol. 60, no. 3, March 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:456124. [Accessed: 07 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)
AuthorIda Hude Dragičević
AuthorSandra Bašić-Kinda
AuthorHelena Markotić
AuthorMartina Morić-Perić
AuthorDino Dujmović
AuthorIvo Radman
AuthorBarbara Dreta
AuthorSnježana Dotlić
AuthorIvana Ilić
AuthorLea Galunić Bilić
AuthorMargareta Dobrenić
AuthorMarko Kralik
AuthorIgor Aurer
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
Background and Objectives: eBEACOPP is the most effective chemotherapy regimen for younger patients with early unfavorable (EU) and advanced-stage (AS) Hodgkin lymphoma (HL), albeit with significant toxicities. The 14-day/cycle prednisone course contributes to side effects, including osteoarticular events like avascular bone necrosis (AVN). Our center has been using eBEACOPP since 2009 for AS and 2014 for EU patients. In 2016, we reduced prednisone treatment to 7–10 days to lessen AVN risk. We analyzed the effects of this approach. Materials and Methods: We retrospectively collected data on patients who received at least two cycles of eBEACOPP for first-line HL treatment. Results: A total of 162 patients (33 EU, 129 AS) were included. Their median age was 31 (range 19–59 years), and 88 were males. A total of 94 patients received full corticosteroid courses, and 68 received reduced corticosteroid courses. The overall response rate (ORR) was 98%. Different corticosteroid dosings had no significant effect on ORR, febrile neutropenia episodes, or hospital admissions. After a median follow-up (mFU) of 58 months, the 5yPFS for the entire cohort was 98% vs. 95% for the standard course vs. the short corticosteroids course, respectively (p = 0.37), while the 5yOS was 98% vs. 99% for the standard course vs. short corticosteroids course, respectively (p = 0.87). In AS patients intended to be treated with six eBEACOPP cycles, 5yPFS and 5yOS were 100% vs. 97% and 100% vs. 99% for standard vs. short corticosteroid courses, respectively (p = 0.56 and p = 0.17). In EU patients, 5yPFS was 97% (standard) vs. 95% (short) (p = 0.98) and 5yOS 100% vs. 93.3% (p = 0.87). Osteoarticular events were numerically lower in patients receiving the shorter prednisone course, both in the whole cohort and in the subgroup of patients treated with six cycles of eBEACOPP, but this difference failed to reach statistical significance. Conclusions: eBEACOPP provides excellent and durable first-line disease control. Shortening the corticosteroid course does not compromise efficacy, potentially reducing toxicity. However, longer follow-ups and larger studies are needed for confirmation.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina
Numberingvol. 60, no. 3, 430
e-ISSN1648-9144
DOIhttps://doi.org/10.3390/medicina60030430
URN:NBNurn:nbn:hr:105:456124
Publication2024-03-02
Document URLhttps://www.mdpi.com/1648-9144/60/3/430
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-10-22 07:22:08